Cargando…

Evaluation of 3D-CEUS in the Recurrence of Liver Cancer after Radiofrequency Ablation

BACKGROUND: Radiofrequency ablation (RFA) has the similar curative effects to surgery, but RFA will lead to higher postoperative local recurrence rate. 3D-CEUS is a minimally invasive examination method, which is used to analyze the sensitivity to postoperative recurrence in this study. METHODS: The...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Lianjie, Wang, Xinping, Shi, Shenglong, Gao, Jian, Li, Xing, Wang, Ying, Jiang, Maitao, Zheng, Chunlei, Liu, Huilin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712161/
https://www.ncbi.nlm.nih.gov/pubmed/34966520
http://dx.doi.org/10.1155/2021/3123553
_version_ 1784623506380554240
author Bai, Lianjie
Wang, Xinping
Shi, Shenglong
Gao, Jian
Li, Xing
Wang, Ying
Jiang, Maitao
Zheng, Chunlei
Liu, Huilin
author_facet Bai, Lianjie
Wang, Xinping
Shi, Shenglong
Gao, Jian
Li, Xing
Wang, Ying
Jiang, Maitao
Zheng, Chunlei
Liu, Huilin
author_sort Bai, Lianjie
collection PubMed
description BACKGROUND: Radiofrequency ablation (RFA) has the similar curative effects to surgery, but RFA will lead to higher postoperative local recurrence rate. 3D-CEUS is a minimally invasive examination method, which is used to analyze the sensitivity to postoperative recurrence in this study. METHODS: The clinical data of 60 patients with liver cancer admitted to our hospital (February 2018-February 2020) were retrospectively analyzed. All patients were treated with RFA and were followed up with 3D-CEUS, MRI, and enhanced CT examination after surgery. The ROC curve was used to analyze the differences of different examination methods in judging postoperative recurrence. RESULTS: For the 60 patients, 52 patients (86.7%) had a single lesion and 8 patients (13.3%) had multiple lesions, with a total of 72 lesions. After RFA, 56 lesions (77.8%) were completely inactivated and 16 lesions (22.2%) remained. Totally inactivated lesions were detected as follows: 51 (91.1%) by 3D-CEUS, 42 (75.0%) by MRI, and 50 (89.3%) by enhanced CT. During a 2-year follow-up, a total of 26 recurrent lesions were detected, 24 (92.3%) by 3D-CEUS, 12 (46.2%) by MRI, and 25 (96.2%) by enhanced CT, indicating that the sensitivity of 3D-CEUS and enhanced CT was obviously higher than that of MRI (P < 0.001), without conspicuous difference between sensitivity of 3D-CEUS and enhanced CT (P > 0.05). CONCLUSION: As a new imaging examination method based on artificial intelligence, 3D-CEUS has a high sensitivity in patients with liver cancer who underwent RFA, which can effectively judge the recurrence after surgery and should be widely used in practice.
format Online
Article
Text
id pubmed-8712161
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-87121612021-12-28 Evaluation of 3D-CEUS in the Recurrence of Liver Cancer after Radiofrequency Ablation Bai, Lianjie Wang, Xinping Shi, Shenglong Gao, Jian Li, Xing Wang, Ying Jiang, Maitao Zheng, Chunlei Liu, Huilin J Healthc Eng Research Article BACKGROUND: Radiofrequency ablation (RFA) has the similar curative effects to surgery, but RFA will lead to higher postoperative local recurrence rate. 3D-CEUS is a minimally invasive examination method, which is used to analyze the sensitivity to postoperative recurrence in this study. METHODS: The clinical data of 60 patients with liver cancer admitted to our hospital (February 2018-February 2020) were retrospectively analyzed. All patients were treated with RFA and were followed up with 3D-CEUS, MRI, and enhanced CT examination after surgery. The ROC curve was used to analyze the differences of different examination methods in judging postoperative recurrence. RESULTS: For the 60 patients, 52 patients (86.7%) had a single lesion and 8 patients (13.3%) had multiple lesions, with a total of 72 lesions. After RFA, 56 lesions (77.8%) were completely inactivated and 16 lesions (22.2%) remained. Totally inactivated lesions were detected as follows: 51 (91.1%) by 3D-CEUS, 42 (75.0%) by MRI, and 50 (89.3%) by enhanced CT. During a 2-year follow-up, a total of 26 recurrent lesions were detected, 24 (92.3%) by 3D-CEUS, 12 (46.2%) by MRI, and 25 (96.2%) by enhanced CT, indicating that the sensitivity of 3D-CEUS and enhanced CT was obviously higher than that of MRI (P < 0.001), without conspicuous difference between sensitivity of 3D-CEUS and enhanced CT (P > 0.05). CONCLUSION: As a new imaging examination method based on artificial intelligence, 3D-CEUS has a high sensitivity in patients with liver cancer who underwent RFA, which can effectively judge the recurrence after surgery and should be widely used in practice. Hindawi 2021-12-20 /pmc/articles/PMC8712161/ /pubmed/34966520 http://dx.doi.org/10.1155/2021/3123553 Text en Copyright © 2021 Lianjie Bai et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Bai, Lianjie
Wang, Xinping
Shi, Shenglong
Gao, Jian
Li, Xing
Wang, Ying
Jiang, Maitao
Zheng, Chunlei
Liu, Huilin
Evaluation of 3D-CEUS in the Recurrence of Liver Cancer after Radiofrequency Ablation
title Evaluation of 3D-CEUS in the Recurrence of Liver Cancer after Radiofrequency Ablation
title_full Evaluation of 3D-CEUS in the Recurrence of Liver Cancer after Radiofrequency Ablation
title_fullStr Evaluation of 3D-CEUS in the Recurrence of Liver Cancer after Radiofrequency Ablation
title_full_unstemmed Evaluation of 3D-CEUS in the Recurrence of Liver Cancer after Radiofrequency Ablation
title_short Evaluation of 3D-CEUS in the Recurrence of Liver Cancer after Radiofrequency Ablation
title_sort evaluation of 3d-ceus in the recurrence of liver cancer after radiofrequency ablation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712161/
https://www.ncbi.nlm.nih.gov/pubmed/34966520
http://dx.doi.org/10.1155/2021/3123553
work_keys_str_mv AT bailianjie evaluationof3dceusintherecurrenceoflivercancerafterradiofrequencyablation
AT wangxinping evaluationof3dceusintherecurrenceoflivercancerafterradiofrequencyablation
AT shishenglong evaluationof3dceusintherecurrenceoflivercancerafterradiofrequencyablation
AT gaojian evaluationof3dceusintherecurrenceoflivercancerafterradiofrequencyablation
AT lixing evaluationof3dceusintherecurrenceoflivercancerafterradiofrequencyablation
AT wangying evaluationof3dceusintherecurrenceoflivercancerafterradiofrequencyablation
AT jiangmaitao evaluationof3dceusintherecurrenceoflivercancerafterradiofrequencyablation
AT zhengchunlei evaluationof3dceusintherecurrenceoflivercancerafterradiofrequencyablation
AT liuhuilin evaluationof3dceusintherecurrenceoflivercancerafterradiofrequencyablation